COMP <GO>
OMCL vs ZEPP // REVENUE GROWTH (YOY)
Omnicell Inc. ($0.001 par value) (NASDAQ) VS. Zepp Health Corporation each representing sixteen (Class A) (NYSE) • 15-METRIC TALLY: OMCL 8
— ZEPP 1
▲ REVENUE GROWTH (YOY) LEADER: ZEPP
LAST: $36.88 (+2.59%) • MKT CAP: $1.68B
revenue-growth
6.50%
ZEPP — Zepp Health Corporation each representing sixteen (Class A) SUPERIOR
ROARABLE D- • RQD 35/100
LAST: $2.25 (-3.85%) • MKT CAP: $33.0M
revenue-growth
41.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OMCL VS. ZEPP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OMCL | ZEPP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 42.50% | 38.30% | +4.20 | OMCL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.40% | -14.70% | +15.10 | OMCL | /roic <GO> |
| EV/EBITDA & P/E Valuation | 37.6x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 5.16% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 0.40% | -11.30% | +11.70 | OMCL | /operating-margins <GO> |
| Net Profit Margin | 0.20% | -15.50% | +15.70 | OMCL | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 6.50% | 41.80% | -35.30 | ZEPP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.36 | 0.33 | +2.03 | OMCL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 5/9 | +2.00 | OMCL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.5 | 11.4 | +44.04 | OMCL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.68B | $33.0M | $1.65B | OMCL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OMCL REV | ZEPP REV | OMCL GROSS % | ZEPP GROSS % | OMCL FCF | ZEPP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.18B | $258.9M | 42.5% | 38.3% | $86.9M | -$26.2M |
| FY 2024 | $1.11B | $182.6M | 42.3% | 38.5% | $151.3M | -$25.8M |
| FY 2023 | $1.15B | $352.9M | — | — | $181.1M | $42.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OMCL // BETA —
ZEPP // BETA —